Stock Ticker

  • Loading stock data...

Discontinuation of Suboxone Tablet Supply Boosts Prospects of Titan Pharmaceuticals (TTNP)

Reckitt Benckiser’s decision to discontinue the supply of Suboxone tablets could not have come at a better time for Titan Pharmaceuticals (OTC: TTNP). Titan is well positioned to bring out new drug applications for buprenorphine-based products for treatment of opioid addiction and dependence. Reckitt Benckiser’s voluntary withdrawal decision was based on the analysis of data […]

Titan Pharmaceuticals Receives Giant Size Offer (TTNP)

Traders were anything but sedate today when it came to buying shares of Titan Pharmaceuticals (OTC: TTNP). About two hours after the opening of the trading session, the company announced it had an agreement to sell 3.4 million shares of common stock to a potential licensee of the rights to commercialize Titan’s drug Probuphine, which […]

Titan Pharmaceuticals Announces $4.25 Million Stock Purchase Agreement to Commercialize Probuphine (TTNP)

Titan Pharmaceuticals (OTC: TTNP) has taken another step forward in its quest to develop treatment options for opioid dependence using the substance Probuphine. The company has just entered a Stock Purchase and Option Agreement with an affiliate company that is a potential licensee of the commercialization rights of Probuphine. The $4.25 million Stock Purchase and […]

Titan Pharmaceuticals Falls Through the Floor (TTNP)

Titan Pharmaceuticals (OTC: TTNP) released second quarter results this morning that showed revenues doubling to $1.4 million from the same period in 2011. The top line consisted of royalties on the net sales of Fanapt. Operating expenses in the quarter decreased by 36% from one year ago. For the quarter, the company reported a net of […]

Sign Up To Get Our Latest Stocks Alerts